Cerity Partners
FATE icon

Cerity Partners’s Fate Therapeutics FATE Stock Holding History

Cerity Partners’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$854K Buy
341,732
+228,188
+201% +$422K ﹤0.01% 2088
2026
Q1 		$136K Buy
113,544
+61,055
+116% +$74.3K ﹤0.01% 2973
2025
Q4 		$51.6K Buy
52,489
+1,672
+3% +$2.01K ﹤0.01% 2802
2025
Q3 		$64K Buy
50,817
+19,810
+64% +$21.4K ﹤0.01% 2670
2025
Q2 		$32.9K Buy
31,007
+1,103
+4% +$1.28K ﹤0.01% 2581
2025
Q1 		$23.6K Sell
29,904
-793,230
-96% -$972K ﹤0.01% 2446
2024
Q4 		$28.2K Buy
823,134
+806,846
+4,954% +$2.03M ﹤0.01% 2397
2024
Q3 		$57K Buy
16,288
+272
+2% +$1.06K ﹤0.01% 2477
2024
Q2 		$52.5K Sell
16,016
-790
-5% -$3.46K ﹤0.01% 2172
2024
Q1 		$123K Sell
16,806
-15,368
-48% -$95.1K ﹤0.01% 2178
2023
Q4 		$120K Buy
+32,174
New +$75.9K ﹤0.01% 1772
2023
Q3 		– Sell
-31,950
Closed -$152K – 1494
2023
Q2 		$152K Buy
+31,950
New +$176K ﹤0.01% 1515
2020
Q1 		– Sell
-10,070
Closed -$197K – 469
2019
Q4 		$197K Buy
+10,070
New +$160K 0.01% 508
2018
Q3 		– Sell
-13,920
Closed -$158K – 547
2018
Q2 		$158K Hold
13,920
– – 0.01% 520
2018
Q1 		$136K Hold
13,920
– – 0.01% 508
2017
Q4 		$85K Hold
13,920
– – 0.01% 551
2017
Q3 		$55K Buy
+13,920
New +$47.3K ﹤0.01% 563
2017
Q2 		– Sell
-13,920
Closed -$63K – 375
2017
Q1 		$63K Buy
+13,920
New +$50.9K 0.01% 430

Other funds holding FATE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Cerity Partners's FATE Position: Q2 2026 in Review

Cerity Partners increased its Fate Therapeutics (FATE) stake by 201% in Q2 2026, buying an estimated $422K and bringing the position to 341,732 shares worth $854K. The position accounts for ﹤0.01% of the portfolio, ranked #2088.

Cerity Partners first reported a position in FATE in Q1 2017 and has held it in 18 quarters since. 137 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Cerity Partners held 341,732 shares of Fate Therapeutics worth $854K as of Q2 2026.
  • Cerity Partners bought 228,188 Fate Therapeutics shares in Q2 2026, an estimated $422K.
  • Fate Therapeutics made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #2088 holding.
  • Cerity Partners first reported a position in Fate Therapeutics in Q1 2017 and has held it in 18 quarters since.
  • 137 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.